SCHEMBL5359262

SCHEMBL5359262

ClCc1nnc2ccccn12

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.71
ALDH1A1 P00352 4/20 0.71
RAB9A P51151 9/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
NPC1 O15118 5/20 0.47
HPGD P15428 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
HSD17B10 Q99714 3/20 0.47
KMT2A Q03164 2/20 0.47
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 1/20 0.39
HTR5A P47898 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14759162 0.80 KDM4E (0.71) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL5373208 0.80 KDM4E (0.71) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL8350565 0.80 KDM4E (0.71) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL14759243 0.78 KDM4E (0.69) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL24862850 0.77 KDM4E (0.67) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL7983003 0.77 KDM4E (0.67) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL4866580 0.77 KDM4E (0.79) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL7979647 0.77 KDM4E (0.67) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL24273206 0.77 KDM4E (0.67) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL23959346 0.76 KDM4E (0.65) KDM4EALDH1A1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119569706-A Therapeutic compounds 希四克斯探索有限公司 2025-03-07 CN disclosed
CN-112996785-B Therapeutic compounds 希四克斯探索有限公司 2024-12-06 CN disclosed
CN-112996785-A Therapeutic compounds 希四克斯探索有限公司 2021-06-18 CN disclosed
US-7217711-B2 Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-15 US disclosed
US-20050171093-A1 New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171093-A1 New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions DPP4, DPP3, DPP7 KDM4E 844/4885ALDH1A1 285/4885RAB9A 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.